Akari Therapeutics Sees Cost Savings Through Reduced Clinical Trial, Infrastructure Costs >AKTX
Akari Therapeutics Sees Cost Savings Through Reduced Clinical Trial, Infrastructure Costs >AKTX
Press Release: Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanc
Press Release: Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity -- Prioritization of Peak's ADC cancer therapeutic platform technology and Akari'
Peak Bio's Strategic Merger With Akari Therapeutics
Shareholder Alert: Ademi LLP Investigates Whether Peak Bio Inc. Has Obtained a Fair Price in Its Transaction With Akari
MILWAUKEE, March 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Peak Bio (OTC: PKBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Akari. Click here
Akari Therapeutics Rises on All Stock Deal With Peak Bio
Peak Stockholders Will Receive a Number of Akari Ordinary Shrs for Each Shr of Peak Stk They Own >AKTX
Peak Stockholders Will Receive a Number of Akari Ordinary Shrs for Each Shr of Peak Stk They Own >AKTX
Akari Therapeutics, Peak Bio: Hoyoung Huh, M.D., Ph.D. Expected to Serve as Chairman of Combined Entity >AKTX
Akari Therapeutics, Peak Bio: Hoyoung Huh, M.D., Ph.D. Expected to Serve as Chairman of Combined Entity >AKTX
Akari Therapeutics, Peak Bio: Post-merger Bd of Directors Will Consist of 3 Directors Selected by Each Co and 1 Independent Director Jointly Selected >AKTX
Akari Therapeutics, Peak Bio: Post-merger Bd of Directors Will Consist of 3 Directors Selected by Each Co and 1 Independent Director Jointly Selected >AKTX
Akari Therapeutics And Peak Bio Announce Merger Of Equals; Exchange Is Expected To Result In Implied Equity Ownership In The Combined Company Of Approximately 50% For Akari Shareholders And Approximately 50% For Peak Stockholders
Akari Therapeutics And Peak Bio Announce Merger Of Equals; Exchange Is Expected To Result In Implied Equity Ownership In The Combined Company Of Approximately 50% For Akari Shareholders And Approximat
Akari Therapeutics, Peak Bio Combined Entity Will Operate as Akari Therapeutics and Continue to Be Listed and Trade on Nasdaq Cap Market as AKTX >AKTX
Akari Therapeutics, Peak Bio Combined Entity Will Operate as Akari Therapeutics and Continue to Be Listed and Trade on Nasdaq Cap Market as AKTX >AKTX
Akari Therapeutics, Peak Bio to Merge as Equals in All-Stk Transaction >AKTX PKBO
Akari Therapeutics, Peak Bio to Merge as Equals in All-Stk Transaction >AKTX PKBO
Press Release: Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit BOSTON and PLEASANTON, Calif
Peak Bio Raises Over $2M Through Convertible Notes
Peak Bio Raises Capital via Convertible Promissory Notes
Peak Bio, Inc. Awarded Patent With Broad Coverage for Thailanstatin-ADC Platform Technology (PH-1) a Payload With Novel Immunomodulatory Effects That Target RNA Splicing
Peak Bio, Inc. (OTCQB) PK: PKBO) announced that it was awarded US Patent No. 11,691,982 B2 entitled "Thailanstatin Analogs" by The United States Patent and Trademark Office (USPTO).
Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC Payload Platform Targeting RNA Splicing
Pleasanton, CA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing
Insider Buying: Hoyoung Huh Acquires 47,000 Shares of Peak Bio Inc (PKBO)
Peak Bio(PKBO.US) 10% Shareholder Buys US$23,990.75 in Common Stocks
$Peak Bio(PKBO.US)$ 10% Shareholder Huh Hoyoung purchased 93,250 shares of Common Stocks on Aug 29, 30, 31, 2023 at an average price of $0.257 for a total value of $23,990.75.Source: Announcement What
Peak Bio Up-lists to OTCQB Market
No Data